Novavax partners win US, EU, Japan approvals for XFG-adapted Nuvaxovid for 2026-27 season
NVAX•Partnership approvals support royalty revenue
Sanofi, Takeda hold the approvals under partnership deals, supporting Novavax royalty revenue tied to net sales.
Regulators clear XFG-adapted Nuvaxovid for 2026-2027 season
Regulators cleared an XFG-adapted Nuvaxovid formulation for the 2026-2027 COVID-19 vaccination season in the U.S., EU, Japan.
